Redeye initiates coverage of Precise Biometrics, a global leader in the fingerprint algorithms space...
Redeye provides an update following Enzymatica’s Q1 report.
Q1: growth recovery and margin improvements with solid FCF We tweak our '24e sales and adj.
A miss, but keep in mind Q1 is ~5% of FY EBIT We cut '24e-'26e adj.
Redeye is encouraged to see a slightly higher-than-expected sales development for US CERAMENT G and ...
Redeye provides a first take on Advenica´s first quarter of the year.
Redeye leaves a comment following today’s announcement that Kristina Torfgård has decided to leave h...
Redeye ger en kommentar om de preliminära Q1-siffrorna för Leqembi samt intryck från Biogens Q1-pres...
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
- Clean EBIT SEK 5m vs. ABG SEK 37m - Q2 likely stronger than Q1 - Conference call at 12 CET Clean E...
- Q1: Clean EBITDA NOK -6m - soft compared to our NOK -1m - Targets updated - more achievable - Esti...
Bra orderingång Året har börjat bra för Senzime och den positiva ordertrenden från H2’23 har fortsat...
Fortsatt vikande ARR y/y och q/q… Omsättningen i kvartalet uppgick till 37,3 mkr, vilket motsvarar e...
Lägre försäljning men förbättrad lönsamhet Vi förväntar oss att Orexo visar en nettoomsättning för Q...
God tillväxt och fortsatta interna förbättringar i utmanande miljö Bokusgruppen rapporterade en över...
We note another quarter in which the operations have not yet translated into meaningful sales.
DT’s Q1 earnings were clearly above estimates even though revenue was basically as expected.
Exel’s Q1 results landed below estimates. Demand shows some signs of improvement, but H1’24 results ...
Dovre Q1 results included a write-down of EUR 5.8m related to a single renewable energy project.
Sales +17% y-o-y, +1% vs. ABGSCe EBIT of SEK 21m, -21% vs.
